CYTK Cytokinetics, Incorporated - Common Stock
$76,68
Cena · Sie 19, 2026
Dane fundamentalne na dzień Sie 6, 2026
Zakres 52 tyg.
$35–$88
78% of range
Ocena Analityków
BUY
28 analysts
Cena Docelowa
$110
+43% upside
P/E (TTM)
-11.7
ROE
152.7%
Marża Zysku Netto
-891.6%
O Cytokinetics, Incorporated - Common Stock Przegląd firmy z Wikipedii
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
Czytaj więcej
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
History
Cytokinetics was founded in 1997 by James Spudich, Ronald Vale, James Sabry and Lawrence S.B. Goldstein, four scientists at Stanford, UCSD, and UCSF. Operations began in 1998.
Initially, Cytokinetics focused on the possible pharmacological targets and areas of application of drugs based on cytoskeletal proteins. Eventually, the company narrowed its focus to the mechanics of muscle biology. Cytokinetics develops muscle activators and muscle inhibitors to improve muscle function in patients with cardiovascular and neuromuscular diseases.
In 2004 the company completed its initial public offering (IPO).
In January 2007, Cytokinetics named Robert I. Blum as president and CEO. Prior to this, Blum has been involved in the company since its founding, with roles in business development, corporate development and R&D.
In 2013, Cytokinetics finalized a licensing and discovery deal with Astellas to research treatment for muscle weakness and fatigue.
In July 2020, Ji Xing Pharmaceuticals signed a financing deal with Cytokinetics, which included the rights to commercialize the drug designed to treat hypertrophic cardiomyopathies, aficamten, in China and certain neighboring regions.
Products
Omecamtiv mecarbil is a cardiac muscle activator for the potential treatment of heart failure. In May 2020, omecamtiv mecarbil was granted fast track designation by the FDA for the treatment of chronic HF with reduced ejection fraction. Amgen purchased an option on omecamtiv mecarbil in 2006, and the two companies extended their partnership several times. In June 2013, Cytokinetics and Amgen expanded their licensing deal for omecamtiv mecarbil to include Japan. In November 2020 Amgen elected to terminate the collaboration, effective May 20, 2021, and Cytokinetics regained worldwide rights to develop and commercialize omecamtiv mecarbil.
Reldesemtiv (previously known as CK-2127107) is a next-generation fast skeletal muscle troponin activator (FSTA) that has undergone clinical trials for ALS.
Aficamten (previously known as CK-3773274) is an oral, small-molecule myosin inhibitor, to treat hypertrophic cardiomyopathy (HCM).
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
CYTK Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
Cena
$76.67
Kapitalizacja Rynkowa
$9.43B
P/E (TTM)
-11.7
EPS (TTM)
$-6.54
Przychody (TTM)
$88M
Stopa dywidendy
—
ROE
152.7%
D/E Dług/Kapitał
-0.4
Zakres 52 tyg.
$35 – $88
CYTK Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
Configure
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Przychody i Zysk Netto
$88M
2016-12-31
→
2025-12-31
EPS
$-6.54
2016-12-31
→
2025-12-31
Wolny przepływ pieniężny
$-535M
2016-12-31
→
2025-12-31
Marże
-891.6%
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
Wskaźnik
Trend 5-letni
CYTK
Mediana porównawcza
P/E (TTM)
-11.7
28.5
P/S (TTM)
107.1
20.1
P/B
-14.3
12.9
EV / EBITDA
-15.9
—
Price / FCF (Cena / FCF)
-17.6
—
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
Wskaźnik
Trend 5-letni
CYTK
Mediana porównawcza
Operating Margin (Marża Operacyjna)
-695.4%
—
Net Profit Margin (Marża Zysku Netto)
-891.6%
-48.4%
ROA
-55.5%
-28.4%
ROE
152.7%
-49.2%
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
Wskaźnik
Trend 5-letni
CYTK
Mediana porównawcza
Debt / Equity (Dług / Kapitał Własny)
-0.4
—
Current Ratio (Wskaźnik bieżący)
4.5
5.0
Quick Ratio (Wskaźnik Szybkości)
0.7
—
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
Wskaźnik
Trend 5-letni
CYTK
Mediana porównawcza
Revenue YoY (Przychody R/R)
376.6%
—
Revenue CAGR 3Y (Przychody CAGR 3L)
-2.4%
—
Revenue CAGR 5Y (Przychody CAGR 5L)
9.5%
—
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
Wskaźnik
Trend 5-letni
CYTK
Mediana porównawcza
CYTK Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
KUP
28 analityków
- Mocne kupno 6 21,4%
- Kup 19 67,9%
- Trzymaj 3 10,7%
- Sprzedaj 0 0,0%
- Mocna sprzedaż 0 0,0%
12-miesięczny cel cenowy
20 analityków · 2026-08-18
Mediana
$107.50
← Poniżej wszystkich celów
$76.67
Niski
$85.00
Wysoki
$146.00
Średni cel
$107.50
+40,2%
Średnia cel
$109.90
+43,3%
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
Średnie zaskoczenie
-0.08%
| Okres | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|
| 30 czerwca 2026 | $-1.50 | $-1.67 | 0.17% |
| 31 marca 2026 | $-1.67 | $-1.69 | 0.02% |
| 31 grudnia 2025 | $-1.50 | $-1.49 | -0.01% |
| 30 września 2025 | $-2.55 | $-1.61 | -0.94% |
| 30 czerwca 2025 | $-1.12 | $-1.41 | 0.28% |
| 31 marca 2025 | $-1.39 | $-1.41 | 0.02% |
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| CYTK | $7.81B | -9.7 | 376.6% | -891.6% | 152.7% | — |
| EXEL | $11.44B | 15.7 | 7.0% | 33.7% | 37.3% | — |
| ARWR | $4.68B | -3449.0 | 23258.2% | -0.20% | -0.50% | — |
| MDGL | $13.30B | -45.3 | 432.1% | -30.1% | -44.4% | — |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | — |
| PRAX | $7.43B | -21.9 | 249.5% | — | -47.3% | — |
| SMMT | $13.56B | -12.1 | — | — | -235.1% | — |
| PTGX | $5.47B | -42.6 | -89.4% | -282.8% | -20.3% | — |
| KYMR | $6.33B | -21.1 | -16.7% | -794.0% | -24.4% | — |
| APGE | $5.16B | -17.9 | — | — | — | — |
| KRYS | $7.20B | 36.0 | 33.9% | 52.6% | 18.1% | — |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat 16
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $88M | $18M | $8M | $95M | $70M | $56M | $27M | $32M | $13M | $106M | $29M | $47M | |
| R&D Expense | $416M | $339M | $330M | $241M | $160M | $97M | $86M | $89M | $90M | $60M | $46M | $44M | |
| SG&A Expense | $284M | $215M | $174M | $178M | $97M | $53M | $40M | $31M | $36M | $28M | $20M | $17M | |
| Operating Expenses | $700M | $555M | $504M | $419M | $257M | $150M | $126M | $120M | $127M | $88M | $66M | $62M | |
| Operating Income | $-612M | $-536M | $-496M | $-324M | $-186M | $-94M | $-99M | $-89M | $-113M | $19M | $-37M | $-15M | |
| Interest Expense | $46M | $38M | $28M | $19M | $16M | $16M | $7M | $4M | $3M | $3M | $268.0K | $0 | |
| Interest Income | · | · | · | $11M | $1M | $5M | $4M | $4M | · | $449.0K | $156.0K | $101.0K | |
| Other Non-op | $48M | $52M | $28M | $11M | $331.0K | $5M | $5M | $4M | $3M | $464.0K | $174.0K | $108.0K | |
| Pretax Income | · | · | · | · | · | · | · | $-106M | $-128M | $16M | $-38M | $-15M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-785M | $-590M | $-526M | $-389M | $-215M | $-127M | $-122M | $-106M | $-128M | $16M | $-38M | $-15M | |
| EPS (Basic) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.41 | $-0.97 | $-0.41 | |
| EPS (Diluted) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.39 | $-0.97 | $-0.41 | |
| Shares (Basic) | 120,103 | 111,979 | 96,524 | 89,825 | 76,886 | 64,524 | · | · | 49,404,000 | 39,943,000 | 38,814,000 | 35,709,000 | |
| Shares (Diluted) | 120,103 | 111,979 | 96,524 | 89,825 | 76,886 | 64,524 | · | · | 49,404,000 | 42,561,000 | 38,814,000 | 35,709,000 | |
| EBITDA | $-602M | $-527M | $-484M | $-318M | $-184M | $-92M | $-98M | $-88M | $-111M | $19M | $-37M | $-14M |
Bilans 26
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $123M | $95M | $113M | $66M | $113M | $83M | $36M | $42M | $125M | $67M | $65M | $20M | |
| Receivables | $18M | $17M | $1M | $147.0K | $52M | $4M | $5M | $2M | $1M | $24.0K | · | · | |
| Inventory | $0 | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $17M | $15M | $12M | $12M | $12M | $6M | $3M | $2M | $4M | $2M | $2M | $1M | |
| Other Current Assets | · | · | · | · | · | · | · | · | · | · | · | $1M | |
| Current Assets | $917M | $1.11B | $628M | $795M | $536M | $474M | $234M | $208M | $274M | $159M | $113M | $131M | |
| PP&E (Net) | $79M | $66M | $69M | $80M | $73M | $13M | $5M | $3M | $4M | $4M | $2M | $2M | |
| PP&E (Gross) | $126M | $103M | $97M | $98M | $89M | $38M | $29M | $27M | $26M | $25M | $23M | $22M | |
| Accum. Depreciation | $47M | $37M | $28M | $17M | $16M | $25M | $24M | $24M | $23M | $21M | $21M | $20M | |
| Other Non-current Assets | $17M | $8M | $8M | $10M | $7M | $6M | · | $300.0K | $429.0K | $200.0K | $200.0K | $200.0K | |
| Total Assets | $1.42B | $1.40B | $824M | $1.01B | $841M | $534M | $290M | $211M | $295M | $170M | $115M | $133M | |
| Accounts Payable | $22M | $20M | $22M | $26M | $21M | $8M | $8M | $4M | $5M | $4M | $2M | $1M | |
| Accrued Liabilities | $83M | $55M | $43M | $44M | $34M | $19M | $12M | $16M | $17M | $18M | $8M | $5M | |
| Current Liabilities | $202M | $180M | $103M | $85M | $72M | $31M | $26M | $22M | $32M | $33M | $32M | $24M | |
| Capital Leases | $108M | $113M | $120M | $127M | $112M | $440.0K | $2M | $771.0K | · | · | · | · | |
| Other Non-current Liabilities | · | $0 | $186.0K | $1M | $4M | $0 | · | $771.0K | $1M | $142.0K | · | · | |
| Total Liabilities | $2.08B | $1.54B | $1.21B | $1.12B | $597M | $420M | $301M | $185M | $185M | $76M | $47M | $41M | |
| Long-term Debt | $288M | $620M | $639M | $650M | · | $46M | $45M | $42M | $32M | $30M | $15M | · | |
| Total Debt | $288M | $105M | $68M | $64M | $47M | $46M | $45M | $42M | $32M | $30M | $15M | · | |
| Common Stock | $123.0K | $118.0K | $102.0K | $94.0K | $84.0K | $70.0K | $59.0K | $55.0K | $54.0K | $41.0K | $40.0K | $39.0K | |
| Paid-in Capital | · | · | · | · | $1.45B | · | · | · | · | · | · | $589M | |
| Retained Earnings | $-3.49B | $-2.70B | $-2.11B | $-1.59B | $-1.21B | $-992M | $-865M | $-743M | $-646M | $-518M | $-535M | $-497M | |
| AOCI | $630.0K | $2M | $-10.0K | $-4M | $-869.0K | $149.0K | $679.0K | $500.0K | $343.0K | $137.0K | $149.0K | $-4.0K | |
| Stockholders' Equity | $-660M | $-135M | $-386M | $-108M | $244M | $113M | $-11M | $26M | $110M | $94M | $69M | $92M | |
| Liabilities + Equity | $1.42B | $1.40B | $824M | $1.01B | $841M | $534M | $290M | $211M | $295M | $170M | $115M | $133M | |
| Shares Outstanding | 122,943,172 | 118,209,139 | 101,637,922 | 94,833,975 | 84,799,542 | 71,015,183 | 59,172,124 | 54,717,906 | 53,960,832 | 40,646,595 | 39,581,692 | 38,659,738 |
Przepływy pieniężne 16
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $10M | $10M | $12M | $6M | $2M | $2M | $1M | $1M | $2M | $741.0K | $589.0K | $490.0K | |
| Stock-based Comp | $112M | $98M | $72M | $48M | $27M | $18M | $11M | $10M | $9M | $7M | $5M | $3M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Other Non-cash | $153M | $86M | $28M | $36M | $44M | $117M | $19M | $-6M | $15M | $13M | $37M | $-34M | |
| Operating Cash Flow | $-510M | $-396M | $-414M | $-300M | $-143M | $9M | $-91M | $-101M | $-102M | $37M | $5M | $-45M | |
| CapEx | $25M | $4M | $1M | $11M | $49M | $11M | $3M | $889.0K | $3M | $2M | $562.0K | $1M | |
| Investing Cash Flow | $17M | $-553M | $239M | $-262M | $-148M | $-197M | $-75M | $5M | $-66M | · | · | · | |
| Net Debt Issued | $-11M | $-9M | · | $-48M | · | · | · | · | · | · | · | · | |
| Stock Issued | · | · | $164M | · | $0 | $0 | $36M | $0 | $112M | $0 | $9M | $49M | |
| Net Stock Activity | · | · | $164M | · | $0 | $0 | $36M | $0 | $112M | $0 | $9M | $49M | |
| Financing Cash Flow | $524M | $931M | $221M | $516M | $320M | $234M | $160M | $13M | $226M | · | · | · | |
| Net Change in Cash | $30M | $-18M | $46M | $-45M | $30M | $47M | $-6M | $-83M | $58M | $2M | $45M | $57.0K | |
| Taxes Paid | $0 | $0 | $0 | · | · | · | · | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | |
| Free Cash Flow | $-535M | $-400M | $-416M | $-311M | $-191M | $-2M | $-94M | $-102M | $-105M | $35M | $4M | $-46M | |
| Levered FCF | · | · | · | · | · | · | · | $-106M | $-108M | $33M | · | $-46M |
Rentowność 7
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% | -168.3% | -368.0% | -282.3% | -848.3% | 17.6% | -130.5% | -31.4% | |
| Net Margin | -891.6% | -3191.1% | -6988.6% | -411.2% | -305.7% | -228.0% | -452.9% | -337.4% | -955.9% | 15.5% | -130.9% | -31.2% | |
| Pretax Margin | · | · | · | · | · | · | · | -337.4% | -955.9% | 15.5% | -130.9% | -31.2% | |
| EBITDA Margin | -683.9% | -2851.1% | -6431.8% | -336.6% | -261.3% | -165.0% | -363.2% | -278.3% | -833.9% | 18.3% | -128.5% | -30.4% | |
| ROA | -55.5% | -53.0% | -57.2% | -41.9% | -31.3% | -30.9% | -48.6% | -42.0% | -55.0% | 11.5% | -30.2% | -13.6% | |
| ROE | 152.7% | 789.8% | 127.6% | 628.0% | -87.4% | -96.8% | 790.0% | -272.5% | -125.2% | 20.2% | -46.7% | -20.0% | |
| ROIC | · | · | · | · | · | · | · | -130.1% | -80.1% | 15.0% | -44.9% | -16.0% |
Płynność i wypłacalność 5
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.5 | 6.2 | 6.1 | 9.4 | 7.5 | 15.2 | 9.0 | 9.4 | 8.5 | 4.8 | 3.6 | 5.5 | |
| Quick Ratio | 0.7 | 0.6 | 1.1 | 0.8 | 2.3 | 2.8 | 1.6 | 2.0 | 3.9 | 2.0 | 2.1 | 0.8 | |
| Debt / Equity | -0.4 | -0.8 | -0.2 | -0.6 | 0.2 | 0.4 | -4.1 | 1.6 | 0.3 | 0.3 | 0.2 | · | |
| LT Debt / Equity | -0.4 | -0.7 | -0.2 | -0.6 | 0.2 | 0.4 | -4.1 | 1.5 | 0.3 | 0.3 | 0.2 | · | |
| Interest Coverage | -13.4 | -14.2 | -17.5 | -16.7 | -11.3 | -5.9 | -14.9 | -23.4 | -37.6 | 6.9 | · | · |
Efektywność 2
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.7 | 0.2 | 0.4 | |
| Receivables Turnover | 5.1 | 2.1 | 10.5 | 3.6 | 2.5 | 11.7 | 7.3 | 18.8 | 23.5 | · | · | · |
Stopy Wzrostu 3
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 376.6% | 145.3% | -92.0% | 34.3% | 26.2% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -2.4% | -36.0% | -48.7% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 9.5% | · | · | · | · | · | · | · | · | · | · | · |
Wycena (TTM) 14
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $88M | $18M | $8M | $95M | $70M | $56M | $27M | $32M | $13M | $106M | $29M | $47M | |
| Net Income TTM | $-785M | $-590M | $-526M | $-389M | $-215M | $-127M | $-122M | $-106M | $-128M | $16M | $-38M | $-15M | |
| Market Cap | $7.81B | $5.56B | $8.49B | $4.35B | $3.87B | $1.48B | $628M | $346M | $440M | $494M | $414M | $310M | |
| Enterprise Value | $7.98B | $5.57B | $8.44B | $4.34B | $3.80B | $1.44B | $636M | $346M | $346M | $457M | $364M | · | |
| P/E | -9.7 | -8.9 | -15.3 | -10.6 | -16.3 | -10.5 | · | · | -3.1 | 31.2 | -10.8 | -19.5 | |
| P/S | 88.7 | 301.0 | 1126.9 | 45.9 | 54.9 | 26.4 | 23.4 | 11.0 | 32.9 | 4.6 | 14.4 | 6.6 | |
| P/B | -11.8 | -41.1 | -22.0 | -40.3 | 15.8 | 13.0 | -57.4 | 13.3 | 4.0 | 5.2 | 6.0 | 3.4 | |
| P / Tangible Book | · | · | · | · | 15.8 | 13.0 | · | · | · | · | · | · | |
| P / Cash Flow | -15.3 | -14.0 | -20.5 | -14.5 | -27.1 | 165.0 | -6.9 | -3.4 | -4.3 | 13.4 | 84.8 | -6.9 | |
| P / FCF | -14.6 | -13.9 | -20.4 | -14.0 | -20.2 | -699.7 | -6.7 | -3.4 | -4.2 | 14.0 | 95.8 | -6.7 | |
| EV / EBITDA | -13.2 | -10.6 | -17.4 | -13.6 | -20.6 | -15.6 | -6.5 | -3.9 | -3.1 | 23.5 | -9.9 | · | |
| EV / FCF | -14.9 | -13.9 | -20.3 | -14.0 | -19.9 | -682.3 | -6.8 | -3.4 | -3.3 | 12.9 | 84.1 | · | |
| EV / Revenue | 90.6 | 301.5 | 1121.0 | 45.9 | 54.0 | 25.8 | 23.7 | 11.0 | 25.9 | 4.3 | 12.7 | · | |
| Earnings Yield | -10.3% | -11.2% | -6.5% | -9.4% | -6.1% | -9.5% | · | · | -31.8% | 3.2% | -9.3% | -5.1% |
Rachunek zysków i strat 14
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29M | $19M | $18M | $2M | $67M | $2M | $17M | $463.0K | $249.0K | $835.0K | $2M | $378.0K | $867.0K | $5M | $2M | $3M | |
| R&D Expense | $98M | $96M | $104M | $99M | $110M | $98M | $94M | $85M | $80M | $82M | $85M | $83M | $83M | $79M | $75M | $63M | |
| SG&A Expense | $104M | $105M | $92M | $69M | $66M | $57M | $62M | $57M | $51M | $46M | $44M | $40M | $40M | $50M | $54M | $48M | |
| Operating Expenses | $208M | $203M | $196M | $169M | $178M | $157M | $156M | $141M | $130M | $127M | $129M | $123M | $123M | $129M | $129M | $111M | |
| Operating Income | $-179M | $-184M | $-178M | $-167M | $-112M | $-156M | $-139M | $-141M | $-130M | $-126M | $-127M | $-122M | $-122M | $-124M | $-127M | $-108M | |
| Interest Expense | · | · | $14M | $11M | $11M | · | $9M | $9M | $13M | $7M | $7M | $7M | $7M | $7M | $7M | $7M | |
| Interest Income | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $4M | |
| Other Non-op | $14M | $11M | $11M | $10M | $13M | $14M | $15M | $17M | $12M | $8M | $8M | $7M | $7M | $6M | $6M | $4M | |
| Net Income | $-199M | $-206M | $-183M | $-306M | $-134M | $-161M | $-150M | $-161M | $-143M | $-136M | $-137M | $-129M | $-129M | $-131M | $-137M | $-142M | |
| EPS (Basic) | $-1.50 | $-1.67 | $-1.51 | $-2.55 | $-1.12 | $-1.36 | $-1.26 | $-1.36 | $-1.31 | $-1.33 | $-1.38 | $-1.35 | $-1.34 | $-1.38 | $-1.53 | $-1.52 | |
| EPS (Diluted) | $-1.50 | $-1.67 | $-1.51 | $-2.55 | $-1.12 | $-1.36 | $-1.26 | $-1.36 | $-1.31 | $-1.33 | $-1.38 | $-1.35 | $-1.34 | $-1.38 | $-1.53 | $-1.52 | |
| Shares (Basic) | 132,086 | 123,273 | -237,832 | 119,982 | 119,457 | 118,496 | -216,870 | 117,685 | 109,240 | 101,924 | -190,466 | 96,071 | 95,755 | 95,164 | -174,660 | 93,758 | |
| Shares (Diluted) | 132,086 | 123,273 | -237,832 | 119,982 | 119,457 | 118,496 | -216,870 | 117,685 | 109,240 | 101,924 | -190,466 | 96,071 | 95,755 | 95,164 | -174,660 | 93,758 | |
| EBITDA | $-179M | $-180M | · | $-167M | $-112M | $-153M | · | $-141M | $-130M | $-124M | · | $-122M | $-122M | $-123M | · | $-108M |
Bilans 24
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $255M | $130M | $123M | $225M | $75M | $74M | $95M | $47M | $190M | $120M | · | $100M | $69M | $102M | · | $106M | |
| Receivables | $24M | $7M | $18M | $2M | $8M | $2M | $17M | $244.0K | $0 | $834.0K | · | $2M | $985.0K | $1M | · | $2M | |
| Inventory | $380.0K | $154.0K | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $18M | $14M | $17M | $13M | $20M | $16M | $15M | $7M | $11M | $19M | · | $20M | $20M | $16M | · | $14M | |
| Current Assets | $1.21B | $839M | $917M | $977M | $887M | $956M | $1.11B | $1.02B | $1.07B | $639M | · | $561M | $587M | $681M | · | $884M | |
| PP&E (Net) | $79M | $82M | $79M | $76M | $70M | $67M | $66M | $64M | $66M | $68M | · | $76M | $77M | $79M | · | $80M | |
| PP&E (Gross) | · | · | $126M | · | · | · | $103M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $47M | · | · | · | $37M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $19M | $18M | $17M | $17M | $15M | $13M | $8M | $8M | $8M | $8M | · | $8M | $8M | $8M | · | · | |
| Total Assets | $1.92B | $1.27B | $1.42B | $1.44B | $1.23B | $1.26B | $1.40B | $1.44B | $1.52B | $808M | · | $741M | $780M | $890M | · | $1.08B | |
| Accounts Payable | $21M | $25M | $22M | $22M | $16M | $14M | $20M | $12M | $9M | $13M | · | $14M | $13M | $17M | · | $14M | |
| Accrued Liabilities | $77M | $69M | $83M | $62M | $52M | $43M | $55M | $50M | $40M | $40M | · | $33M | $31M | $36M | · | $40M | |
| Current Liabilities | $181M | $199M | $202M | $142M | $131M | $160M | $180M | $110M | $103M | $89M | · | $78M | $66M | $75M | · | $76M | |
| Capital Leases | $102M | $105M | $108M | $111M | $111M | $113M | $113M | $115M | $117M | $119M | · | $122M | $124M | $125M | · | $114M | |
| Other Non-current Liabilities | · | · | · | $2M | $2M | $3M | · | $0 | $0 | $2.0K | · | $408.0K | $625.0K | $837.0K | · | $1M | |
| Total Liabilities | $2.10B | $2.10B | $2.08B | $1.96B | $1.59B | $1.53B | $1.54B | $1.45B | $1.42B | $1.20B | · | $1.18B | $1.11B | $1.12B | · | $1.09B | |
| Long-term Debt | $276M | $292M | $288M | $1.00B | $610M | $610M | $105M | $620M | $629M | $630M | · | · | · | · | · | · | |
| Total Debt | $276M | $292M | · | $176M | $173M | $105M | · | $105M | $104M | $68M | · | $61M | $62M | $64M | · | $64M | |
| Common Stock | $138.0K | $124.0K | $123.0K | $122.0K | $119.0K | $119.0K | $118.0K | $118.0K | $117.0K | $105.0K | · | $94.0K | $94.0K | $94.0K | · | $93.0K | |
| Retained Earnings | $-3.89B | $-3.69B | $-3.49B | $-3.30B | $-3.00B | $-2.86B | $-2.70B | $-2.55B | $-2.39B | $-2.25B | · | $-1.98B | $-1.85B | $-1.72B | · | $-1.45B | |
| AOCI | $-4M | $-2M | $630.0K | $34.0K | $-158.0K | $2M | $2M | $5M | $-1M | $-539.0K | · | $-874.0K | $-1M | $-2M | · | $-6M | |
| Stockholders' Equity | $-173M | $-827M | $-660M | $-521M | $-369M | $-266M | $-135M | $-14M | $109M | $-396M | $-386M | $-439M | $-333M | $-229M | $-108M | $-16M | |
| Liabilities + Equity | $1.92B | $1.27B | $1.42B | $1.44B | $1.23B | $1.26B | $1.40B | $1.44B | $1.52B | $808M | · | $741M | $780M | $890M | · | $1.08B | |
| Shares Outstanding | · | · | 122,943,172 | · | · | · | 118,209,139 | · | · | · | · | · | · | · | · | · |
Przepływy pieniężne 12
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $6M | $2M | $2M | $2M | $2M | $1M | |
| Stock-based Comp | $36M | $30M | $31M | $31M | $28M | $24M | $26M | $25M | $25M | $22M | $19M | $19M | $19M | $15M | $13M | $13M | |
| Other Non-cash | · | $27M | · | · | · | $4M | · | · | · | $-18M | · | · | · | $-8M | · | · | |
| Operating Cash Flow | $-160M | $-145M | $-143M | $-108M | $-128M | $-132M | $-66M | $-102M | $-99M | $-130M | $-74M | $-96M | $-122M | $-122M | $-98M | $-84M | |
| CapEx | $4M | $6M | $6M | $9M | $4M | $6M | $1M | $701.0K | $2M | $0 | $77.0K | $220.0K | $717.0K | $402.0K | $3M | $6M | |
| Investing Cash Flow | $-507M | $145M | $-71M | $-71M | $53M | $106M | $111M | $-45M | $-652M | $33M | $-81M | $73M | $82M | $165M | $29M | $-292M | |
| Net Debt Issued | · | $-3M | · | · | · | $-3M | · | · | · | $-705.0K | · | · | · | · | · | · | |
| Stock Issued | · | · | · | · | $0 | $0 | · | · | · | $94M | · | · | · | $0 | · | · | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $94M | · | · | · | · | · | · | |
| Financing Cash Flow | $793M | $8M | $111M | $330M | $79M | $5M | $2M | $3M | $821M | $104M | $169M | $54M | $5M | $-7M | $30M | $389M | |
| Net Change in Cash | $125M | $7M | $-103M | $152M | $2M | $-21M | $48M | $-143M | $70M | $7M | $13M | $31M | $-34M | $36M | $-39M | $13M | |
| Free Cash Flow | · | $-151M | · | · | · | $-137M | · | · | · | $-130M | · | · | · | $-123M | · | · |
Rentowność 5
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -626.0% | -948.7% | · | -8613.4% | -167.0% | -9856.3% | · | -30410.6% | -52277.9% | -15118.0% | · | -32345.2% | -14077.2% | -2698.3% | · | -4311.8% | |
| Net Margin | -694.4% | -1064.5% | · | -15815.0% | -201.3% | -10220.1% | · | -34675.0% | -57557.4% | -16244.7% | · | -34238.6% | -14837.0% | -2846.1% | · | -5658.4% | |
| EBITDA Margin | -626.0% | -931.2% | · | -8613.4% | -167.0% | -9710.6% | · | -30410.6% | -52277.9% | -14838.8% | · | -32345.2% | -14077.2% | -2658.2% | · | -4311.8% | |
| ROA | -12.6% | -16.2% | · | -21.3% | -9.8% | -15.6% | · | -14.8% | -12.4% | -16.0% | · | -14.2% | -16.6% | -15.0% | · | -14.9% | |
| ROE | 73.3% | 37.7% | · | 114.5% | 103.3% | 48.7% | · | 70.9% | 127.6% | 43.4% | · | 56.9% | 116.1% | 232.9% | · | -122.1% |
Płynność i wypłacalność 5
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.7 | 4.2 | · | 6.9 | 6.8 | 6.0 | · | 9.3 | 10.4 | 7.2 | · | 7.2 | 8.9 | 9.0 | · | 11.6 | |
| Quick Ratio | 1.5 | 0.7 | · | 1.6 | 0.6 | 0.5 | · | 0.4 | 1.9 | 1.4 | · | 1.3 | 1.1 | 1.4 | · | 1.4 | |
| Debt / Equity | -1.6 | -0.4 | · | -0.3 | -0.5 | -0.4 | · | -7.5 | 1.0 | -0.2 | · | -0.1 | -0.2 | -0.3 | · | -4.0 | |
| LT Debt / Equity | -1.4 | -0.3 | · | -0.3 | -0.4 | -0.3 | · | -6.7 | 0.9 | -0.1 | · | -0.1 | -0.2 | -0.3 | · | -4.0 | |
| Interest Coverage | · | · | · | -14.7 | -10.1 | · | · | -15.8 | -10.2 | -17.8 | · | -17.1 | -17.3 | -17.9 | · | -15.9 |
Efektywność 2
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 1.7 | 4.4 | · | 1.9 | 15.9 | 1.1 | · | 0.3 | 0.5 | 0.9 | · | 0.2 | 0.6 | 1.3 | · | 1.7 |
Wycena (TTM) 4
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $117M | $90M | · | $71M | $69M | $3M | · | $2M | $2M | $7M | · | $8M | $97M | $97M | · | $98M | |
| Net Income TTM | $-845M | $-808M | · | $-762M | $-600M | $-601M | · | $-569M | $-537M | $-525M | · | $-532M | $-422M | $-383M | · | $-328M | |
| P/E | -12.5 | -9.8 | · | -8.6 | -6.4 | -7.5 | · | -9.9 | -10.2 | -13.0 | · | -5.3 | -7.3 | -8.4 | · | -12.9 | |
| Earnings Yield | -8.0% | -10.2% | · | -11.6% | -15.6% | -13.3% | · | -10.1% | -9.8% | -7.7% | · | -19.0% | -13.7% | -11.9% | · | -7.7% |
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
Rachunek zysków i strat
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Przychody | $88M | $18M | $8M | $95M | $70M |
| Marża Operacyjna % | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% |
| Zysk netto | $-785M | $-590M | $-526M | $-389M | $-215M |
| Rozwodniony EPS | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 |
Bilans
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Dług / Kapitał Własny | -0.4 | -0.8 | -0.2 | -0.6 | 0.2 |
| Wskaźnik bieżący | 4.5 | 6.2 | 6.1 | 9.4 | 7.5 |
| Wskaźnik Szybkości | 0.7 | 0.6 | 1.1 | 0.8 | 2.3 |
Przepływy pieniężne
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $-535M | $-400M | $-416M | $-311M | $-191M |
Najnowsze wiadomości Najnowsze nagłówki wspominające o tej firmie
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
📊
Wybierz metryki, które są dla Ciebie ważne — kliknij ➕ obok dowolnego wiersza w Pełnych Fundamentach powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Właściciele instytucjonalni (13F) 539 emitentów · $9.0B łącznie · Na dzień 30 czerwca 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
Aktywność instytucjonalna — Q2 2026 vs poprzedni kwartał
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 104 (+7 vs poprzedni kw.) | 49 (-8 vs poprzedni kw.) | 222 (+45 vs poprzedni kw.) | 112 (-32 vs poprzedni kw.) | +17.8M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| VANGUARD PORTFOLIO MANAGEMENT LLC | $571 778 157 | 6 711 799 | 6,37% | Akcje |
| STATE STREET CORP | $553 243 709 | 6 494 233 | 6,16% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $521 151 103 | 6 117 515 | 5,80% | Akcje |
| WELLINGTON MANAGEMENT GROUP LLP | $509 521 049 | 5 980 996 | 5,68% | Akcje |
| Avoro Capital Advisors LLC | $425 949 915 | 4 999 999 | 4,74% | Akcje |
| FMR LLC | $375 035 430 | 4 402 341 | 4,18% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $259 207 450 | 3 042 018 | 2,89% | Akcje |
| BANK OF AMERICA CORP /DE/ | $251 706 463 | 2 954 648 | 2,80% | Akcje |
| RTW INVESTMENTS, LP | $243 814 036 | 2 862 003 | 2,72% | Akcje |
| Polar Capital Holdings Plc | $191 988 358 | 2 253 649 | 2,14% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $161 060 214 | 1 890 600 | 1,79% | Opcja kupna |
| Capital Research Global Investors | $143 683 584 | 1 686 625 | 1,60% | Akcje |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $136 597 224 | 1 603 442 | 1,52% | Akcje |
| Integral Health Asset Management, LLC | $136 304 000 | 1 600 000 | 1,52% | Akcje |
| Point72 Asset Management, L.P. | $135 257 185 | 1 587 712 | 1,51% | Akcje |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $133 386 924 | 1 565 758 | 1,49% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $131 998 327 | 1 549 458 | 1,47% | Akcje |
| PRINCIPAL FINANCIAL GROUP INC | $111 435 932 | 1 308 087 | 1,24% | Akcje |
| Capital International Investors | $111 245 191 | 1 305 848 | 1,24% | Akcje |
| ARMISTICE CAPITAL, LLC | $106 487 500 | 1 250 000 | 1,19% | Opcja kupna |
| ARMISTICE CAPITAL, LLC | $102 342 325 | 1 201 342 | 1,14% | Akcje |
| Pictet Asset Management Holding SA | $99 038 455 | 1 160 463 | 1,10% | Akcje |
| Frazier Life Sciences Management, L.P. | $98 810 092 | 1 159 879 | 1,10% | Akcje |
| Holocene Advisors, LP | $97 506 685 | 1 144 579 | 1,09% | Akcje |
| Woodline Partners LP | $93 769 315 | 1 100 708 | 1,04% | Akcje |
| NORGES BANK | $86 512 319 | 1 015 522 | 0,96% | Akcje |
| Royalty Pharma Sub-Manager, LLC | $83 519 594 | 980 392 | 0,93% | Akcje |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $81 937 000 | 961 815 | 0,91% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $77 218 175 | 906 423 | 0,86% | Akcje |
| CITADEL ADVISORS LLC | $77 062 874 | 904 600 | 0,86% | Opcja kupna |
| Melqart Asset Management (UK) Ltd | $65 385 455 | 767 525 | 0,73% | Akcje |
| Siren, L.L.C. | $64 655 121 | 758 952 | 0,72% | Akcje |
| Fisher Asset Management, LLC | $63 355 547 | 743 697 | 0,71% | Akcje |
| Foresite Capital Management IV, LLC | $60 884 867 | 714 695 | 0,68% | Akcje |
| Balyasny Asset Management L.P. | $60 599 821 | 711 349 | 0,67% | Akcje |
| Deep Track Capital, LP | $59 633 000 | 700 000 | 0,66% | Akcje |
| JANE STREET GROUP, LLC | $59 633 000 | 700 000 | 0,66% | Opcja kupna |
| BNP PARIBAS FINANCIAL MARKETS | $58 702 470 | 689 077 | 0,65% | Akcje |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. | $56 251 809 | 660 310 | 0,63% | Akcje |
| CITADEL ADVISORS LLC | $54 601 338 | 640 936 | 0,61% | Akcje |
| GOLDMAN SACHS GROUP INC | $54 053 311 | 634 503 | 0,60% | Akcje |
| Qube Research & Technologies Ltd | $48 774 257 | 572 535 | 0,54% | Akcje |
| EVENTIDE ASSET MANAGEMENT, LLC | $48 081 832 | 564 398 | 0,54% | Akcje |
| Affinity Asset Advisors, LLC | $46 854 500 | 550 000 | 0,52% | Akcje |
| First Turn Management, LLC | $44 930 228 | 527 412 | 0,50% | Akcje |
| AMERICAN CENTURY COMPANIES INC | $44 162 525 | 518 398 | 0,49% | Akcje |
| Caption Management, LLC | $43 651 356 | 512 400 | 0,49% | Opcja kupna |
| D. E. Shaw & Co., Inc. | $40 874 247 | 479 801 | 0,46% | Akcje |
| Checkpoint Capital L.P. | $40 465 250 | 475 000 | 0,45% | Akcje |
| Hood River Capital Management LLC | $39 977 367 | 469 273 | 0,45% | Akcje |
| RP Management, LLC | $39 401 954 | 980 392 | 0,44% | Akcje |
| EMERALD ADVISERS, LLC | $39 013 272 | 457 956 | 0,43% | Akcje |
| ADAR1 Capital Management, LLC | $39 009 097 | 457 907 | 0,43% | Akcje |
| AMERIPRISE FINANCIAL INC | $38 010 006 | 446 179 | 0,42% | Akcje |
| Candriam S.C.A. | $37 708 477 | 443 066 | 0,42% | Akcje |
| MARSHALL WACE, LLP | $36 259 335 | 425 629 | 0,40% | Akcje |
| RHUMBLINE ADVISERS | $35 933 015 | 421 799 | 0,40% | Akcje |
| CITADEL ADVISORS LLC | $35 882 028 | 421 200 | 0,40% | Opcja sprzedaży |
| ALLIANCEBERNSTEIN L.P. | $35 327 299 | 535 993 | 0,39% | Akcje |
| GILDER GAGNON HOWE & CO LLC | $34 096 829 | 400 245 | 0,38% | Akcje |
| TD Asset Management Inc | $32 809 225 | 385 130 | 0,37% | Akcje |
| BlackRock, Inc. | $29 124 928 | 341 882 | 0,32% | Akcje |
| GSK plc | $29 001 573 | 340 434 | 0,32% | Akcje |
| TWO SIGMA INVESTMENTS, LP | $27 040 243 | 317 411 | 0,30% | Akcje |
| CITIGROUP INC | $26 852 314 | 315 205 | 0,30% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $24 671 024 | 289 600 | 0,27% | Opcja sprzedaży |
| Trails Edge Capital Partners, LP | $24 542 302 | 288 089 | 0,27% | Akcje |
| EMERALD MUTUAL FUND ADVISERS TRUST | $23 833 521 | 279 769 | 0,27% | Akcje |
| Polaris Capital Management, LLC | $22 737 211 | 266 900 | 0,25% | Akcje |
| SEGALL BRYANT & HAMILL, LLC | $21 899 197 | 257 063 | 0,24% | Akcje |
| Alyeska Investment Group, L.P. | $21 297 500 | 250 000 | 0,24% | Akcje |
| ExodusPoint Capital Management, LP | $21 234 374 | 249 259 | 0,24% | Akcje |
| Capital World Investors | $21 196 550 | 248 815 | 0,24% | Akcje |
| Walleye Capital LLC | $20 422 428 | 239 728 | 0,23% | Akcje |
| E. Ohman J:or Asset Management AB | $19 823 223 | 300 762 | 0,22% | Akcje |
| Sarissa Capital Management LP | $19 476 393 | 228 623 | 0,22% | Akcje |
| Swiss National Bank | $18 946 256 | 222 400 | 0,21% | Akcje |
| SPHERA FUNDS MANAGEMENT LTD. | $18 740 693 | 219 987 | 0,21% | Akcje |
| BAKER BROS. ADVISORS LP | $17 997 836 | 211 267 | 0,20% | Akcje |
| California Public Employees Retirement System | $17 979 520 | 211 052 | 0,20% | Akcje |
| Nicholas Investment Partners, LP | $17 810 758 | 209 071 | 0,20% | Akcje |
| PINNACLE ASSOCIATES LTD | $17 245 864 | 202 440 | 0,19% | Akcje |
| Mirador Capital Partners LP | $17 239 900 | 202 370 | 0,19% | Akcje |
| Tri Locum Partners LP | $16 526 860 | 194 000 | 0,18% | Akcje |
| PFM Health Sciences, LP | $16 329 730 | 191 686 | 0,18% | Akcje |
| Rock Springs Capital Management LP | $16 014 016 | 187 980 | 0,18% | Akcje |
| PRUDENTIAL FINANCIAL INC | $15 933 512 | 187 035 | 0,18% | Akcje |
| DAFNA Capital Management LLC | $14 652 510 | 171 998 | 0,16% | Akcje |
| Ghisallo Capital Management LLC | $14 482 300 | 170 000 | 0,16% | Akcje |
| Impax Asset Management Group plc | $14 056 350 | 165 000 | 0,16% | Akcje |
| Lombard Odier Asset Management (Europe) Ltd | $13 494 096 | 158 400 | 0,15% | Opcja kupna |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | $13 383 349 | 157 100 | 0,15% | Akcje |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $13 330 276 | 156 477 | 0,15% | Akcje |
| JANE STREET GROUP, LLC | $12 735 905 | 149 500 | 0,14% | Opcja sprzedaży |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $12 145 719 | 139 190 | 0,14% | Akcje |
| Retirement Systems of Alabama | $11 962 891 | 140 426 | 0,13% | Akcje |
| MetLife Investment Management, LLC | $11 930 519 | 140 046 | 0,13% | Akcje |
| Polymer Capital Management (HK) LTD | $11 777 943 | 138 255 | 0,13% | Akcje |
| Cinctive Capital Management LP | $11 742 419 | 137 838 | 0,13% | Akcje |
| TUDOR INVESTMENT CORP ET AL | $11 279 156 | 132 400 | 0,13% | Opcja kupna |
Insiderzy spółki 52 insiderów · 18 dyrektorzy generalni · 22 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Sung Lee | EVP, Chief Financial Officer | 1 lipca 2026 M | 63 221 | 0 | 5 | $-5 695 855 |
| Ching Jaw | SVP Finance & CFO | 6 marca 2023 A | 87 346 | 0 | 0 | $0 |
| Sharon Surrey Barbari | EVP, Finance & CFO | 28 lutego 2017 F | 40 323 | 0 | 0 | $0 |
| Fady Ibraham Malik | EVP Research & Development | 18 sierpnia 2026 M | 153 902 | 0 | 22 | $-4 429 370 |
| Andrew Callos | EVP, Chief Commercial Officer | 30 lipca 2026 M | 58 555 | 0 | 24 | $-15 318 893 |
| Jeffrey Hessekiel | Chief Legal & Admin Officer | 15 marca 2026 A | 107 943 | 0 | 0 | $0 |
| Robert Wong | VP, Chief Accounting Officer | 3 grudnia 2024 A | 18 655 | 0 | 0 | $0 |
| Brett A Pletcher | EVP, Chief Legal Officer | 30 sierpnia 2024 A | 33 140 | 0 | 0 | $0 |
| Mark A Schlossberg | SVP - Legal & General Counsel | 15 marca 2022 M | 103 408 | 0 | 0 | $0 |
| David Cragg | Chief HR & Admin Officer | 7 marca 2022 F | 153 233 | 0 | 0 | $0 |
| Caryn Gordon Mcdowell | GC & Chief Compliance Officer | 27 lutego 2018 A | 32 548 | 0 | 0 | $0 |
| Peter S Roddy | SVP Finance & CAO | 27 lutego 2018 A | 21 520 | 0 | 0 | $0 |
| Bradley Paul Morgan | SVP Drug Discovery & Early Dev | 31 sierpnia 2017 M | 46 441 | 0 | 0 | $0 |
| Bonnie Charpentier | SVP Regulatory & Compliance | 28 lutego 2017 A | 29 004 | 0 | 0 | $0 |
| Andrew A Wolff | SVP & CMO | 28 lutego 2017 A | 47 255 | 0 | 0 | $0 |
| David J Morgans JR | EVP-Preclinical R&D | 28 lutego 2011 A | 42 000 | 0 | 0 | $0 |
| Michael Rabson | SVP Business Dev/Legal & GC | 18 grudnia 2009 M | 20 043 | 0 | 0 | $0 |
| Jay K Trautman | VP, Discovery Research | 29 lutego 2008 A | 47 896 | 0 | 0 | $0 |
| Robert Arthur Harrington | Dyrektor | 15 lipca 2026 A | 21 932 | 0 | 2 | $-248 260 |
| James M Daly | Dyrektor | 15 lipca 2026 A | 3 390 | 0 | 0 | $0 |
| Edward M. Kaye MD | Dyrektor | 15 lipca 2026 A | 10 434 | 0 | 6 | $-3 544 372 |
| Nancy Wysenski | Dyrektor | 15 lipca 2026 A | 33 992 | 0 | 0 | $0 |
| Wendell Wierenga | Dyrektor | 15 lipca 2026 A | 35 563 | 0 | 3 | $-1 881 925 |
| John T Henderson | Dyrektor | 15 lipca 2026 A | 78 360 | 0 | 2 | $-2 078 525 |
| Lynne B Parshall | Dyrektor | 1 czerwca 2026 S | 15 784 | 0 | 3 | $-1 000 100 |
| Muna Bhanji | Dyrektor | 27 maja 2026 A | 26 361 | 0 | 0 | $0 |
| Robert E Landry | Dyrektor | 27 maja 2026 A | 10 184 | 0 | 0 | $0 |
| Wendall Wierenga | Dyrektor | 15 lipca 2025 A | 32 345 | 0 | 0 | $0 |
| COSTA SANTO J | Dyrektor | 15 maja 2024 A | 20 600 | 0 | 0 | $0 |
| Sandford D Smith | Dyrektor | 2 stycznia 2024 A | 18 801 | 0 | 0 | $0 |
| Robert Califf | Dyrektor | 3 stycznia 2022 A | 6 003 | 0 | 0 | $0 |
| GAGE L PATRICK | Dyrektor | 8 listopada 2021 M | 28 932 | 0 | 0 | $0 |
| Denise Gilbert | Dyrektor | 20 maja 2015 J | — | 0 | 0 | $0 |
| Stephen M Dow | Dyrektor | 2 stycznia 2013 A | 1 421 052 | 0 | 0 | $0 |
| James A Spudich | Dyrektor | 18 maja 2011 A | 180 600 | 0 | 0 | $0 |
| Grant A Heidrich III | Dyrektor | 3 stycznia 2011 A | 93 755 | 0 | 0 | $0 |
| Michael Schmertzler | Dyrektor | 3 czerwca 2010 S | 4 340 923 | 0 | 0 | $0 |
| Mark Mcdade | Dyrektor | 21 maja 2009 A | — | 0 | 0 | $0 |
| Charles J Homcy | Dyrektor | 22 maja 2008 A | — | 0 | 0 | $0 |
| William J Rutter | Dyrektor | 29 kwietnia 2004 C | 172 413 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VI LP | Posiadacz 10% | 29 kwietnia 2004 C | 1 615 716 | 0 | 0 | $0 |
| SRB ASSOCIATES VIII LP | Posiadacz 10% | 29 kwietnia 2004 C | 771 052 | 0 | 0 | $0 |
| SRB ASSOCIATES VII LP | Posiadacz 10% | 29 kwietnia 2004 C | 650 000 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VIII LP | Posiadacz 10% | 29 kwietnia 2004 C | 755 631 | 0 | 0 | $0 |
| Robert I Blum | — | 10 sierpnia 2026 M | 377 820 | 0 | 19 | $-9 702 097 |
| Elisabeth Schnieders | — | 28 lutego 2017 A | 43 919 | 0 | 0 | $0 |
| James H Sabry | — | 3 czerwca 2010 M | 0 | 0 | 0 | $0 |
| SEVIN ROSEN VII AFFILIATES FUND LP | — | 29 kwietnia 2004 C | 24 050 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VII LP | — | 29 kwietnia 2004 C | 625 950 | 0 | 0 | $0 |
| SRB ASSOCIATES VI LP | — | 29 kwietnia 2004 C | 1 742 951 | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Posiadanie ETF-ów Posiadane przez 84 fundusze ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| LFSC · RBB Fund, Inc. | 3,16% | 43 268 NS | 31 maja 2026 | N-PORT |
| HRTS · Tema ETF Trust | 2,52% | 17 069 NS | 31 maja 2026 | N-PORT |
| PTH · Invesco Exchange-Traded Fund Trust | 1,81% | 58 136 SH | 8 sierpnia 2026 | Dziennie |
| FMED · Fidelity Covington Trust | 1,55% | 8 262 NS | 31 maja 2026 | N-PORT |
| GDOC · Goldman Sachs ETF Trust | 1,40% | 3 663 NS | 31 maja 2026 | N-PORT |
| JSMD · Janus Detroit Street Trust | 1,24% | 189 801 NS | 30 kwietnia 2026 | N-PORT |
| JSML · Janus Detroit Street Trust | 0,98% | 48 338 NS | 30 kwietnia 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,94% | 76 297 NS | 30 kwietnia 2026 | N-PORT |
| IBB · iShares Trust | 0,75% | 874 995 SH | 8 sierpnia 2026 | Dziennie |
| BBC · ETFis Series Trust I | 0,75% | 4 355 NS | 30 kwietnia 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,71% | 7 377 SH | 8 sierpnia 2026 | Dziennie |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,64% | 102 933 SH | 8 sierpnia 2026 | Dziennie |
| IWN · iShares Trust | 0,62% | 1 099 434 SH | 8 sierpnia 2026 | Dziennie |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,51% | 41 612 NS | 30 kwietnia 2026 | N-PORT |
| BIB · ProShares Trust | 0,47% | 4 553 NS | 31 maja 2026 | N-PORT |
| NUSC · Nushares ETF Trust | 0,47% | 94 565 NS | 30 kwietnia 2026 | N-PORT |
| MIDE · DBX ETF Trust | 0,41% | 178 NS | 29 maja 2026 | N-PORT |
| DWAS · Invesco Exchange-Traded Fund Trust … | 0,37% | 21 543 SH | 8 sierpnia 2026 | Dziennie |
| XJH · iShares Trust | 0,35% | 18 349 SH | 8 sierpnia 2026 | Dziennie |
| IQSM · New York Life Investments ETF Trust | 0,34% | 16 959 NS | 30 kwietnia 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,34% | 761 130 SH | 8 sierpnia 2026 | Dziennie |
| IWM · iShares Trust | 0,34% | 3 349 200 SH | 8 sierpnia 2026 | Dziennie |
| IVOG · VANGUARD ADMIRAL FUNDS | 0,33% | 72 343 SH | 8 sierpnia 2026 | Dziennie |
| VBK · VANGUARD INDEX FUNDS | 0,32% | 1 797 986 SH | 8 sierpnia 2026 | Dziennie |
| IVOO · VANGUARD ADMIRAL FUNDS | 0,32% | 219 413 SH | 8 sierpnia 2026 | Dziennie |
| IJK · iShares Trust | 0,32% | 429 311 SH | 8 sierpnia 2026 | Dziennie |
| ISCG · iShares Trust | 0,32% | 38 968 SH | 8 sierpnia 2026 | Dziennie |
| IVOV · VANGUARD ADMIRAL FUNDS | 0,31% | 53 623 SH | 8 sierpnia 2026 | Dziennie |
| IJH · iShares Trust | 0,30% | 4 684 495 SH | 8 sierpnia 2026 | Dziennie |
| IJJ · iShares Trust | 0,29% | 317 724 SH | 8 sierpnia 2026 | Dziennie |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,26% | 55 086 NS | 30 kwietnia 2026 | N-PORT |
| ITWO · ProShares Trust | 0,25% | 6 062 NS | 31 maja 2026 | N-PORT |
| RSSL · Global X Funds | 0,23% | 51 834 NS | 30 kwietnia 2026 | N-PORT |
| PTMC · Pacer Funds Trust | 0,23% | 14 028 NS | 30 kwietnia 2026 | N-PORT |
| MVV · ProShares Trust | 0,22% | 4 565 NS | 31 maja 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,21% | 635 330 NS | 31 maja 2026 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0,20% | 19 862 NS | 30 kwietnia 2026 | N-PORT |
| ESML · iShares Trust | 0,20% | 72 711 SH | 8 sierpnia 2026 | Dziennie |
| SCHM · SCHWAB STRATEGIC TRUST | 0,19% | 356 940 NS | 31 maja 2026 | N-PORT |
| FFSM · FIDELITY COVINGTON TRUST | 0,19% | 37 821 NS | 30 kwietnia 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,17% | 40 586 SH | 8 sierpnia 2026 | Dziennie |
| ISCB · iShares Trust | 0,16% | 5 525 SH | 8 sierpnia 2026 | Dziennie |
| MIDU · Direxion Shares ETF Trust | 0,15% | 2 025 NS | 30 kwietnia 2026 | N-PORT |
| UMDD · ProShares Trust | 0,15% | 638 NS | 31 maja 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,15% | 11 444 NS | 30 kwietnia 2026 | N-PORT |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,15% | 47 609 NS | 30 kwietnia 2026 | N-PORT |
| UWM · ProShares Trust | 0,15% | 4 765 NS | 31 maja 2026 | N-PORT |
| SMDX · Tidal Trust III | 0,15% | 2 868 NS | 30 kwietnia 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0,14% | 3 113 794 SH | 8 sierpnia 2026 | Dziennie |
| VHT · VANGUARD WORLD FUND | 0,14% | 333 056 SH | 8 sierpnia 2026 | Dziennie |